SCHEMBL8224955

SCHEMBL8224955

OCC1CC2(CC2)CN1Cc1ccccc1

nearest known ligand 0.50

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
GRM6 O15303 1/20 0.43
GBA1 P04062 1/20 0.42
SIGMAR1 Q99720 2/20 0.41
SPHK2 Q9NRA0 3/20 0.40
SPHK1 Q9NYA1 3/20 0.40
MEN1 O00255 1/20 0.39
ALDH1A1 P00352 1/20 0.39
CYP2C9 P11712 1/20 0.39
TSHR P16473 1/20 0.39
CYP2C19 P33261 1/20 0.39
KMT2A Q03164 1/20 0.39
HIF1A Q16665 1/20 0.39
CYP2D6 P10635 1/20 0.38
MAPT P10636 1/20 0.38
NPY1R P25929 1/20 0.37
HTT P42858 1/20 0.37
NPY2R P49146 1/20 0.37
OPRK1 P41145 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14885473 1.00 GRM6 (0.43) GRM6GBA1SIGMAR1SPHK2SPHK1
SCHEMBL25332623 0.94 CYP2D6 (0.43) GRM6GBA1SIGMAR1SPHK2SPHK1
SCHEMBL25332617 0.94 CYP2D6 (0.43) GRM6GBA1SIGMAR1SPHK2SPHK1
SCHEMBL25332628 0.93 CYP2D6 (0.42) GRM6GBA1SIGMAR1SPHK2SPHK1
SCHEMBL25332625 0.93 CYP2D6 (0.42) GRM6GBA1SIGMAR1SPHK2SPHK1
SCHEMBL17973110 0.83 CYP2D6 (0.37) GRM6GBA1SIGMAR1SPHK2SPHK1
SCHEMBL8142711 0.81 GBA1 (0.46) GRM6GBA1SIGMAR1SPHK2SPHK1
SCHEMBL14959515 0.79 SIGMAR1 (0.42) GRM6GBA1SIGMAR1SPHK2SPHK1
SCHEMBL12187945 0.79 SIGMAR1 (0.42) GRM6GBA1SIGMAR1SPHK2SPHK1
SCHEMBL16716374 0.78 SIGMAR1 (0.41) GRM6GBA1SIGMAR1SPHK2SPHK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2794593-B1 SPIRO AMINIC COMPOUNDS AS OREXIN ANTAGONISTS Rottapharm Biotech Srl (IT) 2017-02-01 EP disclosed
US-8921573-B2 Processes for the preparation of novel benzimidazole derivatives ENANTA PHARMACEUTICALS, INC. (US) 2014-12-30 US disclosed
US-20140357653-A1 CHEMICAL COMPOUNDS ROTTAPHARM BIOTECH S.R.L. (IT) 2014-12-04 US disclosed
US-20140316143-A1 PROCESSES FOR THE PREPARATION OF NOVEL BENZIMIDAZOLE DERIVATIVES ENANTA PHARMACEUTICALS, INC. (US) 2014-10-23 US disclosed
US-20120231998-A1 ORGANIC COMPOUNDS AND THEIR USES NOVARTIS AG (CH) 2012-09-13 US disclosed
US-20070286842-A1 Organic Compounds and Their Uses NOVARTIS AG (CH) 2007-12-13 US disclosed
WO-2007133865-A2 HCV/HIV INHIBITORS AN THEIR USES NOVARTIS AG (CH) 2007-11-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070286842-A1 Organic Compounds and Their Uses OAT, OTC, AOX1 GRM6 3317/4885GBA1 764/4885SIGMAR1 861/4885
US-20140316143-A1 PROCESSES FOR THE PREPARATION OF NOVEL BENZIMIDAZOLE DERIVATIVES MAVS, HAVCR2, EIF2AK2 GRM6 4753/4885GBA1 654/4885SIGMAR1 3193/4885
US-20120231998-A1 ORGANIC COMPOUNDS AND THEIR USES OAT, OTC, AOX1 GRM6 3317/4885GBA1 764/4885SIGMAR1 861/4885
US-20140357653-A1 CHEMICAL COMPOUNDS HCRTR2, HCRTR1, NPY1R GRM6 1111/4885GBA1 1462/4885SIGMAR1 126/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.